PT - JOURNAL ARTICLE AU - Tappe, Beeke AU - Lauruschkat, Chris D. AU - Strobel, Lea AU - Pantaleón García, Jezreel AU - Kurzai, Oliver AU - Rebhan, Silke AU - Kraus, Sabrina AU - Pfeuffer-Jovic, Elena AU - Bussemer, Lydia AU - Possler, Lotte AU - Held, Matthias AU - Hünniger, Kerstin AU - Kniemeyer, Olaf AU - Schäuble, Sascha AU - Brakhage, Axel A. AU - Panagiotou, Gianni AU - White, P. Lewis AU - Einsele, Hermann AU - Löffler, Jürgen AU - Wurster, Sebastian TI - COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds AID - 10.1101/2022.04.21.22274082 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.21.22274082 4099 - http://medrxiv.org/content/early/2022/04/22/2022.04.21.22274082.short 4100 - http://medrxiv.org/content/early/2022/04/22/2022.04.21.22274082.full AB - Patients suffering from coronavirus disease-2019 (COVID-19) are at high risk for deadly secondary fungal infections such as COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM). Despite this clinical observation, direct experimental evidence for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-driven alterations of antifungal immunity is scarce. Using an ex-vivo whole blood (WB) stimulation assay, we challenged blood from twelve COVID-19 patients with Aspergillus fumigatus and Rhizopus arrhizus antigens and studied the expression of activation, maturation, and exhaustion markers, as well as cytokine secretion. Compared to healthy controls, T-helper cells from COVID-19 patients displayed increased expression levels of the exhaustion marker PD-1 and weakened A. fumigatus- and R. arrhizus-induced activation. While baseline secretion of proinflammatory cytokines was massively elevated, WB from COVID-19 patients elicited diminished release of T-cellular (e.g., IFN-γ, IL-2) and innate immune cell-derived (e.g., CXCL9, CXCL10) cytokines in response to A. fumigatus and R. arrhizus antigens. Additionally, samples from COVID-19 patients showed deficient granulocyte activation by mold antigens and reduced fungal killing capacity of neutrophils. These features of weakened anti-mold immune responses were largely decoupled from COVID-19 severity, the time elapsed since diagnosis of COVID-19, and recent corticosteroid uptake, suggesting that impaired anti-mold defense is a common denominator of the underlying SARS-CoV-2 infection. Taken together, these results expand our understanding of the immune predisposition to post-viral mold infections and could inform future studies of immunotherapeutic strategies to prevent and treat fungal superinfections in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant of the Stiftung zur Foerderung der Krebsforschung an der Universitaet Wuerzburg (Forschung hilft), grant allocation number 8607630 (to CDL and JL); Nachweis von Immunzellbotenstoffen gegen Covid-19 fuer die Diagnostik und Impfstofftestung. The study was further supported by the Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center CRC124 FungiNet Pathogenic fungi and their human host: Networks of interaction, DFG project number 210879364 (project A1 to AAB, A2 to HE and JL, C3 to OKu, and Z2 to OKn).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee Institut fuer Pharmakologie und Toxikologie Versbacher Str. 9 97080 Wuerzburg This study was approved by the Ethics Committee of the University of Wuerzburg (protocol number 152/20). Informed written consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.